Genentech’s Rituxan Fails Against PPMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Late-stage lupus trial is still a wild card for anti-B-cell therapy.
You may also be interested in...
Biogen Idec Retains MS Focus, But It's "More Than Just Tysabri"
Biogen Idec made the case that it is a research-oriented biotech focused on home-grown therapeutic programs at the firm’s March 26 R&D day. It was an elaborately choreographed effort to remind investors that the firm is maintaining its focus on research and doesn’t plan to be a company that simply develops in-licensed products.
Biogen Idec Retains MS Focus, But It's "More Than Just Tysabri"
Biogen Idec made the case that it is a research-oriented biotech focused on home-grown therapeutic programs at the firm’s March 26 R&D day. It was an elaborately choreographed effort to remind investors that the firm is maintaining its focus on research and doesn’t plan to be a company that simply develops in-licensed products.
Side Effects Dampen Neurologists' Enthusiasm For Novel MS Drugs
With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development – from the first oral options to infrequently administered biologics – the treatment paradigm for the debilitating disease appears on the cusp of significant change.